Search
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.
Products: EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120 MG/ML, Pontevia 120 mg solution for injection in pre-filled penHuman interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigationalHuman interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. … [L12078] Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS).
Azathioprine
go.drugbank.com/drugs/DB00993ApprovedInvestigationalAzathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic … [L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Products: AZATHIOPRIN DURA N 25MG, AZATHIOPRIN DURA N 50MGLevocarnitine
go.drugbank.com/drugs/DB00583ApprovedInvestigationalIt is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
Synonyms: 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner saltRimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … It was rejected for approval for use in the United States.
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Aceclidine
go.drugbank.com/drugs/DB13262ApprovedAceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]
Olopatadine
go.drugbank.com/drugs/DB00768ApprovedAn ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.
Ethylenediamine
go.drugbank.com/drugs/DB14189ApprovedIt is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285]. … Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products.